Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Conditions
- Gastric CancerHER2 Overexpressing Gastric Carcinoma
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 351
- Registration Number
- NCT04714190
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT04400695
- Locations
- 🇨🇳
Oncology Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT04329429
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳First Hospital of Jilin University, Chang chun, Jilin, China
🇨🇳Peking University Cancer Hospital & Institute, Beijing, Beijing, China
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT04311034
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04073602
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT03809013
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
- Conditions
- HER2 Overexpressing Gastric CarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 127
- Registration Number
- NCT03556345
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT03507166
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, N/A = Not Applicable, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, N/A = Not Applicable, China
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
- Conditions
- Breast NeoplasmsBreast DiseasesCapecitabineHER2-positive Breast CancerHER2 Positive Breast CarcinomaHER2-positive Advanced Breast With Liver Metastases
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 301
- Registration Number
- NCT03500380
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02881138
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.